Synthetic route optimization of PF-00868554, an HCV polymerase inhibitor in clinical evaluation
This paper describes the optimization efforts to establish an enabling synthesis to provide multigram quantity of PF-00868554, an HCV polymerase inhibitor currently in phase II clinical evaluations.